Skip to search formSkip to main contentSkip to account menu

BCH 4556

Known as: BCH-4556 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
PURPOSE A multi-institution phase II study was undertaken by National Cancer Institute of Canada-Clinical Trials Group to… 
Highly Cited
2002
Highly Cited
2002
PURPOSE To investigate the activity of a novel dioxolane L-nucleoside analog, troxacitabine (L-(-)-OddC, BCH-4556), in patients… 
Highly Cited
2001
Highly Cited
2001
PURPOSE To investigate the toxicity profile, activity, and pharmacokinetics of a novel L-nucleoside analog, troxacitabine (BCH… 
Highly Cited
2001
Highly Cited
2001
Troxacitabine (Troxatyl; BCH-4556; (-)-2'-deoxy-3'-oxacytidine), a deoxycytidine analogue with an unusual dioxolane structure and… 
2000
2000
There is a great need for new therapeutic agents for patients with advanced pancreatic cancer. The new dioxolane analogue… 
2000
2000
Abstract.Purpose: Troxacitabine (β-L-dioxolane cytidine, BCH-4556; Troxatyl, BioChem Pharma Inc.) is a novel nucleoside analogue… 
Highly Cited
2000
Highly Cited
2000
β-l-Dioxolane-cytidine (l-OddC, BCH-4556, Troxacitabine) is a novel unnatural stereochemical nucleoside analog that is under… 
1998
1998
Prostate carcinoma is a common malignancy among males that results in high morbidity and mortality. Here, we have evaluated the… 
1998
1998
BACKGROUND BCH-4556 ((-)-2'-deoxy-3'-oxacytidine) is an L-nucleoside analogue shown to have broad preclinical anti-cancer… 
Highly Cited
1997
Highly Cited
1997
Beta-L-Dioxolane-cytidine (BCH-4556) is a novel anticancer nucleoside analogue with a stereochemically unnatural beta-L…